What Will Novartis Do With $13bn Cash Pile From GSK?
Executive Summary
The Swiss major has divested a non-core asset at a decent price and its eye care unit Alcon could be next under the hammer as CEO Vas Narasimhan looks at bolt-on acquisitions to create "the leading medicines company, powered by digital and data."
You may also be interested in...
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.
Novartis Blows Storm Clouds Off Sandoz US In Aurobindo Sale
Novartis's proposed sale of its generic oral solids portfolio – which has been battered by US price erosion – and the Sandoz US dermatology business to Aurobindo Pharma, in a deal potentially worth $1bn, allows the unit to finally concentrate on biosimilars, value-added medicines and complex generics.
Takeda's Interest Likely To Flush Out Further Shire Suitors
As Takeda discloses that it is considering making a bid to acquire Shire, other big pharma companies look likely to assess their own interest in the firm. Pfizer and AbbVie are among those that may lay their cards on the table.